Benign or malignant cells related to thyroid cancer can be detected by molecular markers, such as BRAF mutation, RAS mutation and RET/PTC rearrangement.[25] Some guidelines (2017 Bethesda guidelines and 2019 NCCN) have recommended that molecular marker testing should be used for the assessment of benign or malignant thyroid nodules, especially in combination with genetic testing. Here, BRAF is linked to thyroid cancer.